[go: up one dir, main page]

IL273076A - Solid dosage form - Google Patents

Solid dosage form

Info

Publication number
IL273076A
IL273076A IL273076A IL27307620A IL273076A IL 273076 A IL273076 A IL 273076A IL 273076 A IL273076 A IL 273076A IL 27307620 A IL27307620 A IL 27307620A IL 273076 A IL273076 A IL 273076A
Authority
IL
Israel
Prior art keywords
dosage form
solid dosage
solid
dosage
Prior art date
Application number
IL273076A
Other languages
Hebrew (he)
Inventor
Beng Stephen Lim Chin
Bruce Sunderland Vivian
Hang Eddy Lee Yip
Original Assignee
Ix Biopharma Ltd
Beng Stephen Lim Chin
Bruce Sunderland Vivian
Hang Eddy Lee Yip
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012238330A external-priority patent/AU2012238330B1/en
Application filed by Ix Biopharma Ltd, Beng Stephen Lim Chin, Bruce Sunderland Vivian, Hang Eddy Lee Yip filed Critical Ix Biopharma Ltd
Publication of IL273076A publication Critical patent/IL273076A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4468Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • A61K38/063Glutathione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL273076A 2012-10-11 2020-03-04 Solid dosage form IL273076A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2012238330A AU2012238330B1 (en) 2010-10-26 2012-10-11 Fast Dissolving Solid Dosage Form
AU2013200684A AU2013200684B1 (en) 2010-10-26 2013-02-08 Fast Dissolving Solid Dosage Form
AU2013200682A AU2013200682C1 (en) 2010-10-26 2013-02-08 Fast Dissolving Solid Dosage Form
PCT/IB2013/002594 WO2014057351A1 (en) 2012-10-11 2013-10-11 Solid dosage form

Publications (1)

Publication Number Publication Date
IL273076A true IL273076A (en) 2020-04-30

Family

ID=50478109

Family Applications (2)

Application Number Title Priority Date Filing Date
IL238104A IL238104B (en) 2012-10-11 2015-04-01 Solid dosage form
IL273076A IL273076A (en) 2012-10-11 2020-03-04 Solid dosage form

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL238104A IL238104B (en) 2012-10-11 2015-04-01 Solid dosage form

Country Status (11)

Country Link
EP (1) EP2906201A4 (en)
JP (1) JP2015533155A (en)
KR (1) KR20150063567A (en)
CN (2) CN104812378B (en)
CA (1) CA2886573C (en)
HK (1) HK1208353A1 (en)
IL (2) IL238104B (en)
MY (1) MY191875A (en)
NZ (1) NZ706302A (en)
SG (1) SG11201502425WA (en)
WO (1) WO2014057351A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6217052B2 (en) * 2016-04-21 2017-10-25 邦赫 小牧 Effervescent tablet for oral cleaning
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
CA3022840A1 (en) 2016-05-05 2017-11-09 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
JP2017193547A (en) * 2017-05-08 2017-10-26 邦赫 小牧 Foaming tablet for oral cleaning
EP3687509A1 (en) * 2017-09-27 2020-08-05 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
WO2019067670A1 (en) * 2017-09-27 2019-04-04 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
IT201800003507A1 (en) * 2018-03-13 2019-09-13 Fulton Medicinali S P A SUBLINGUAL TABLET INCLUDING SILDENAFIL CITRATE
CR20210368A (en) * 2019-01-07 2021-12-10 Antecip Bioventures Ii Llc COMBINATION OF DEXTROMETORPHAN AND BUPROPION FOR THE TREATMENT OF DEPRESSION
CN109846841B (en) * 2019-01-18 2021-06-01 西安力邦医药科技有限责任公司 Quick-acting clobazam oral freeze-dried preparation and preparation method thereof
US20220062200A1 (en) * 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US11382873B1 (en) * 2021-01-08 2022-07-12 Vitalis Analgesics LLC Oral administration of ketamine
EP4422607A4 (en) 2021-10-25 2025-09-03 Aquestive Therapeutics Inc ORAL AND NASAL COMPOSITIONS AND TREATMENT METHODS
WO2025120580A1 (en) * 2023-12-08 2025-06-12 Ix Biopharma Ltd Compositions and methods for initiating a mucosal immune response

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596298B2 (en) * 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
AU2001273545A1 (en) * 2000-07-19 2002-01-30 Lavipharm Laboratories, Inc. Sildenafil citrate solid dispersions having high water solubility
US7118765B2 (en) * 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
US8992974B2 (en) * 2003-02-24 2015-03-31 Pharmaceuticals Productions, Inc. Transmucosal drug delivery system
US20070031349A1 (en) * 2005-06-23 2007-02-08 David Monteith Rapidly absorbing oral formulations of PDE 5 inhibitors
WO2009045022A2 (en) * 2007-10-03 2009-04-09 C.L. Pharm Edible film
KR100905027B1 (en) * 2007-10-03 2009-06-30 (주)씨엘팜 Edible Film
DE102008014533A1 (en) * 2008-03-15 2009-09-17 Lts Lohmann Therapie-Systeme Ag Gingival wafer
US8623401B2 (en) * 2008-03-27 2014-01-07 Fenwafe Inc. Wafer formulation
US8715715B2 (en) * 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
CN102933207B (en) * 2009-10-30 2018-02-02 Ix生物医药有限公司 Fast Dissolving Solid Dosage Forms
EP2549988A1 (en) * 2010-03-23 2013-01-30 Apr Applied Pharma Research S.A. Fast dissolving drug delivery systems
FR2967066B1 (en) * 2010-11-04 2013-06-14 Ethypharm Sa SUBLINGUAL USE OF NON-COMPRESSED MICROGRANULES
JP5841433B2 (en) * 2012-01-11 2016-01-13 日東電工株式会社 Intraoral film-form base and preparation
GB2516561B (en) * 2013-03-15 2016-03-09 Aerpio Therapeutics Inc Compositions, formulations and methods for treating ocular diseases

Also Published As

Publication number Publication date
CN104812378B (en) 2017-12-01
WO2014057351A1 (en) 2014-04-17
IL238104B (en) 2020-03-31
MY191875A (en) 2022-07-18
CA2886573A1 (en) 2014-04-17
CN104812378A (en) 2015-07-29
SG11201502425WA (en) 2015-05-28
NZ706302A (en) 2017-07-28
JP2015533155A (en) 2015-11-19
IL238104A0 (en) 2015-05-31
CA2886573C (en) 2019-04-02
CN107669649A (en) 2018-02-09
EP2906201A4 (en) 2016-10-19
EP2906201A1 (en) 2015-08-19
KR20150063567A (en) 2015-06-09
HK1208353A1 (en) 2016-03-04

Similar Documents

Publication Publication Date Title
IL273076A (en) Solid dosage form
PL3181128T3 (en) Nilotinib pharmaceuticalcomposition
ZA201501930B (en) Pharmaceutical composition
ZA201503594B (en) Pharmaceutical compositions
EP2828262A4 (en) Imidazotriazinone compounds
EP2832730A4 (en) Mirabegron-containing pharmaceutical composition
ZA201405797B (en) Pharmaceutical dosage form
PL2734192T3 (en) Effervescent dosage form
GB201205164D0 (en) Pharmaceutical compounds
PL2925366T3 (en) Pharmaceutical combinations
GB201218012D0 (en) Dosage forms
GB201118334D0 (en) Novel dosage form
IL239512A0 (en) Pharmaceutical compounds
ZA201502987B (en) Pharmaceutical composition
GB2500883B (en) Improved saw-horse
GB201202027D0 (en) Pharmaceutical compounds
GB201413253D0 (en) Solid dosage form
GB201211153D0 (en) Pharmaceutical compositions
GB201113730D0 (en) Solid dosage form
ZA201502354B (en) Pharmaceutical dosage form
GB201222343D0 (en) Novel fast-disolving lactase solid dosage form
GB201219236D0 (en) Pharmaceutical compounds
GB201214121D0 (en) Pharmaceutical compounds
GB201213519D0 (en) Pharmaceutical compounds
GB201203253D0 (en) Pharmaceutical compounds